Article in American journal of physiology. Heart and circulatory physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Mark BroadwinCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.ORCID 0000-0002-0393-9983
Katerina St AngeloDepartment of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, United States.
Max PetersenXM Therapeutics, Inc., Providence, Rhode Island, United States.ORCID 0000-0003-3179-4619
Rayane B TeixeiraCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.
Dwight D HarrisCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.
Christopher R StoneCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.
Cynthia XuCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.ORCID 0000-0002-2191-3066
Meghamsh KanuparthyCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.
Frank W SellkeCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.ORCID 0000-0002-8886-801X
Jeffrey MorganDepartment of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, United States.
M Ruhul AbidCardiovascular Research Center, Rhode Island Hospital, Providence, Rhode Island, United States.ORCID 0000-0003-2981-2638
Funding
Effect of Cardioplegia and Cardiopulmonary Bypass on Coronary Microvascular ReactivityR01HL046716 · NHLBI · RHODE ISLAND HOSPITAL · PI SELLKE, FRANK W · 1997 to 2023
$8.5M
Stem Cells and AgingP30GM145500 · NIGMS · RHODE ISLAND HOSPITAL · PI PETER J. QUESENBERRY · 2023 to 2026
$6.0M
Vascular Dysfunction in Myocardial Ischemia and Metabolic SyndromeR01HL128831 · NHLBI · RHODE ISLAND HOSPITAL · PI SELLKE, FRANK W, USHEVA-SIMIDJIYSKA, ANNY · 2016 to 2025
$5.7M
Trauma and Inflammation Research TrainingT32GM065085 · NIGMS · RHODE ISLAND HOSPITAL · PI Alfred Ayala · 2004 to 2026
$3.2M
Sub-cellular Targeting of Endothelial ROS in Myocardial IschemiaR01HL133624 · NHLBI · RHODE ISLAND HOSPITAL · PI ABID, RUHUL · 2017 to 2020
$1.6M
Cardiovascular Surgery Research TrainingT32HL160517 · NHLBI · RHODE ISLAND HOSPITAL · PI Frank W Sellke · 2022 to 2026
$1.5M
Sub-cellular Targeting of Endothelial ROS in Myocardial IschemiaR56HL133624 · NHLBI · RHODE ISLAND HOSPITAL · PI ABID, RUHUL · 2022 to 2022
$613k
Brown University (BU) Brown University's Biomedical Innovations to Impact fundCOBRE Stem Cells Aging Pilot grant 5P30GM145500HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL46716HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R56HL133624NHLBI NIH HHS R01 HL046716NHLBI NIH HHS R01 HL128831NHLBI NIH HHS R01 HL133624NHLBI NIH HHS R56 HL133624NHLBI NIH HHS T32 HL160517NIGMS NIH HHS P30 GM145500NIGMS NIH HHS T32 GM065085Rhode Island Foundation (RI Foundation) 1472420231352XM Therapeutics via grant to Lifespan/Rhode Island Hospital
6 · The paper itself
Abstract
The promise of injection of extracellular matrix (ECM) from animal hearts as a treatment of myocardial ischemia has been limited by immune reactions and harsh ECM-damaging extraction procedures. We developed a novel method to produce lab-grown human three-dimensional (3-D) acellular ECM particles from human mesenchymal stem cells (MSCs) to mitigate product variability, immunogenicity, and preserve ECM architecture. We hypothesized that intramyocardial injection (I/M) of this novel ECM (dia ∼ 200 microns) would improve cardiac function in a postmyocardial infarction (MI) murine model. WT mice aged 8-10 wk underwent ligation of the left anterior descending coronary (LAD) artery and I/M injection of 10 μL ECM or normal saline (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lab-grown, 3D extracellular matrix particles improve cardiac function and morphology in myocardial ischemia. · full record | OpenQuestion